Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy
| Autor: | Shannon Hancher-Hodges, Morgan L. Bruno, Jonathan A. Wilks, Ching Wei D. Tzeng, Jose M. Soliz, Timothy E. Newhook, Matthew H.G. Katz, Naruhiko Ikoma, Jessica E. Maxwell, Jeffrey E. Lee, Elsa M. Arvide, B. Bryce Speer, Whitney L. Dewhurst, Laura R. Prakash, Michael P. Kim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Blood transfusion medicine.medical_treatment Perineural invasion Adenocarcinoma Gastroenterology Pancreatectomy Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols Humans Medicine Blood Transfusion Prospective Studies Neoadjuvant therapy Aged Retrospective Studies business.industry Hazard ratio General Medicine Perioperative Middle Aged Prognosis medicine.disease Combined Modality Therapy Neoadjuvant Therapy Pancreatic Neoplasms Survival Rate Oncology Pancreatic fistula Female Surgery business Carcinoma Pancreatic Ductal Follow-Up Studies |
| Zdroj: | Journal of Surgical Oncology. 124:1381-1389 |
| ISSN: | 1096-9098 0022-4790 |
| Popis: | BACKGROUND AND OBJECTIVES The impact of perioperative blood transfusion (PBT) on outcomes for pancreatic ductal adenocarcinoma (PDAC) patients given multimodality therapy (MMT) remains undefined. We sought to evaluate the association of PBT with survival after PDAC resection. METHODS Pancreatectomy patients (July 2011-December 2017) who received MMT were abstracted from a prospective database. Overall survival (OS) was compared by PBT within 30 days, 24 h (24HR-BT), or 24 h until 30 days (Postop-BT). RESULTS Most (76.6%) of 312 MMT patients underwent neoadjuvant therapy (NT). Eighty-nine patients (28.5%) received PBT; 58 (18.6%) 24HR-BT, and 31 (9.9%) Postop-BT. Compared with surgery-first, NT patients received more 24HR-BTs (22.2% vs. 6.8%, p = 0.003) and PBTs overall (32.6% vs. 15.1%, p = 0.004). Overall median OS was 45 months. The association of PBT with shorter median OS appeared limited to first 24-h transfusions (34 months 24HR-BT vs. 48 months Postop-BT vs. 53 months no-PBT, p = 0.009) and was dose-dependent, with a median OS of 52 months for 0 units 24HR-BT, 35 months for 1 unit, and 25 months for ≥2 units (p = 0.004). Independent predictors of OS included node-positivity (hazard ratio [HR]: 1.93, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text